NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 14 11:44AM ET
5.12
Dollar change
+0.39
Percentage change
8.12
%
Index- P/E- EPS (ttm)-21.23 Insider Own23.57% Shs Outstand2.33M Perf Week-3.18%
Market Cap11.98M Forward P/E- EPS next Y-17.16 Insider Trans0.00% Shs Float1.79M Perf Month-30.58%
Enterprise Value-38.04M PEG- EPS next Q-4.62 Inst Own34.67% Short Float1.40% Perf Quarter58.18%
Income-49.52M P/S- EPS this Y23.28% Inst Trans-7.27% Short Ratio1.28 Perf Half Y-49.81%
Sales0.00M P/B0.21 EPS next Y6.33% ROA-54.33% Short Interest0.03M Perf YTD-44.61%
Book/sh23.93 P/C0.21 EPS next 5Y22.68% ROE-63.94% 52W High21.84 -76.53% Perf Year-72.97%
Cash/sh23.90 P/FCF- EPS past 3/5Y7.48% 1.53% ROIC-81.50% 52W Low2.69 90.66% Perf 3Y-91.01%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility13.05% 12.66% Perf 5Y-97.70%
Dividend TTM- EV/Sales- EPS Y/Y TTM22.63% Oper. Margin- ATR (14)0.63 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.26 Sales Y/Y TTM- Profit Margin- RSI (14)43.95 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio10.26 EPS Q/Q36.08% SMA20-7.82% Beta1.27 Target Price36.00
Payout- Debt/Eq0.10 Sales Q/Q- SMA50-9.69% Rel Volume6.45 Prev Close4.74
Employees43 LT Debt/Eq0.09 EarningsMay 01 AMC SMA200-46.99% Avg Volume19.59K Price5.12
IPOMay 09, 2019 Option/ShortYes / Yes EPS/Sales Surpr.2.50% - Trades Volume50,355 Change8.12%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-22Initiated Ladenburg Thalmann Buy $16
Mar-05-21Upgrade Truist Hold → Buy $19
Jan-15-21Downgrade BofA Securities Neutral → Underperform $10
Jul-16-20Upgrade The Benchmark Company Hold → Buy $17
Jul-13-20Downgrade SunTrust Buy → Hold
Jul-13-20Downgrade ROTH Capital Buy → Neutral
Jun-01-20Downgrade The Benchmark Company Buy → Hold
Jun-01-20Downgrade BofA/Merrill Buy → Neutral $62 → $40
May-26-20Initiated JMP Securities Mkt Outperform $55
Jun-17-25 05:34AM
Jun-16-25 07:05AM
May-29-25 11:03PM
04:05PM
May-01-25 04:05PM
07:00AM Loading…
Apr-04-25 07:00AM
Mar-06-25 04:05PM
Jan-10-25 08:05AM
Dec-10-24 08:05AM
Nov-26-24 07:00AM
Nov-19-24 08:05AM
Nov-08-24 06:18AM
Nov-07-24 04:05PM
Nov-05-24 04:05PM
Oct-04-24 09:05AM
08:05AM Loading…
Sep-16-24 08:05AM
Aug-01-24 04:05PM
Jun-20-24 04:10PM
May-30-24 04:05PM
May-02-24 09:57PM
04:05PM
Apr-24-24 04:05PM
Apr-08-24 07:00AM
Apr-04-24 07:05AM
Apr-02-24 07:00AM
Mar-23-24 06:00AM
Mar-21-24 10:54PM
11:22AM
08:55AM
Mar-05-24 08:05AM
04:05PM Loading…
Jan-18-24 04:05PM
Dec-25-23 09:55AM
Dec-21-23 07:05AM
Dec-15-23 11:23AM
Dec-14-23 09:14AM
06:45AM
Nov-20-23 07:00AM
Nov-15-23 04:05PM
Nov-07-23 12:00PM
Nov-02-23 06:07PM
04:05PM
Oct-17-23 08:05AM
Sep-26-23 04:05PM
Sep-12-23 08:05AM
Sep-07-23 04:05PM
Sep-05-23 04:05PM
Aug-31-23 07:00AM
Aug-03-23 04:05PM
Jun-21-23 04:05PM
May-11-23 01:58PM
May-09-23 07:00AM
May-04-23 04:05PM
Apr-11-23 07:00AM
Mar-02-23 04:05PM
Feb-07-23 07:00AM
Dec-02-22 10:59AM
Nov-22-22 08:00AM
Nov-16-22 08:09AM
Nov-15-22 04:30PM
Nov-07-22 08:05AM
Nov-03-22 04:15PM
09:15AM
Oct-27-22 04:05PM
Oct-05-22 12:00PM
08:15AM
Oct-04-22 04:05PM
Sep-22-22 08:00AM
Aug-22-22 06:23AM
Aug-04-22 04:05PM
Jul-06-22 08:00AM
Jun-27-22 08:00AM
Jun-25-22 10:26AM
Jun-22-22 08:00AM
Jun-08-22 08:00AM
May-11-22 08:17AM
May-05-22 04:05PM
May-03-22 08:00AM
Apr-19-22 07:30AM
Apr-05-22 08:00AM
Mar-15-22 06:21AM
Mar-03-22 04:05PM
Feb-08-22 08:00AM
Dec-13-21 08:05AM
Nov-30-21 08:00AM
Nov-22-21 08:00AM
Nov-13-21 02:00PM
Nov-04-21 04:05PM
09:15AM
Nov-01-21 08:00AM
Oct-19-21 08:05AM
Oct-07-21 04:05PM
Oct-04-21 08:05AM
Oct-01-21 08:45AM
Sep-29-21 10:41AM
Sep-07-21 07:00AM
Sep-02-21 07:00AM
Aug-05-21 04:05PM
Jul-06-21 04:05PM
Jun-22-21 06:34AM
Jun-21-21 04:05PM
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.